Drug Profile
SpagoPix - Spago Nanomedical
Alternative Names: SN132DLatest Information Update: 27 Dec 2023
Price :
$50
*
At a glance
- Originator Spago NanoMedical
- Class Contrast media; Diagnostic agents; Radiopharmaceutical diagnostics
- Mechanism of Action Magnetic resonance imaging enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Endometriosis
- Phase I Breast cancer
Most Recent Events
- 12 Sep 2023 Spago Nanomedical completes phase-II trial in Endometriosis (Diagnosis) in Sweden (IV) (EudraCT2022-000652-11) (NCT05517447)
- 28 Jun 2023 Adverse events data from phase-IIa SPAGOPIX-02 trial in Endometriosis released by Spago Nanomedical
- 06 Dec 2022 Adverse events and pharmacokinetics data from a phase-I trial were presented at the Annual San Antonio Breast Cancer Symposium (SABCS-2022)